Oncocyte 

$3.17
0
+$0.13+4.35% Wednesday 14:21

통계

낮 최고
3.17
낮음
3.17
52W 높음
4.23
52W 낮음
0.21
거래량
10
평균 거래량
382
시가 총액
26.59B
주가수익률
-
배당수익률
-
배당금
-

예정

수익

7Nov예상
Q3 2022
Q1 2023
Q2 2023
Q3 2023
Q1 2024
Q2 2024
다음
-1.01
-0.7
-0.39
-0.08
예상 EPS
-0.436667
실제 EPS
해당 없음

다른 인물도 팔로우하고 있습니다

이 목록은 Stock Events에서 0KCC.LSE을(를) 팔로우하는 사람들의 워치리스트에 기반한 것입니다. 이는 투자 권유가 아닙니다.

경쟁자

이 목록은 최근 시장 이벤트에 기반한 분석입니다. 투자 권장사항이 아닙니다.

개요

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
Show more...
CEO
Mr. Joshua Riggs
직원
43
국가
US
ISIN
US68235C2061

목록